CEL-SCI Corp. | Ownership
Companies that own CEL-SCI Corp.
Heights Capital Management, Inc.
801,006
3.34%
657,574
0.06%
06/30/2018
The Vanguard Group, Inc.
431,870
1.8%
49,622
0%
06/30/2018
Hudson Bay Capital Management LP
344,611
1.44%
344,611
0.03%
06/30/2018
Anson Funds Management LP
336,500
1.4%
336,500
2.09%
06/30/2018
BlackRock Fund Advisors
125,702
0.52%
37,199
0%
06/30/2018
Geode Capital Management LLC
85,139
0.35%
47,500
0%
06/30/2018
Citadel Advisors LLC
82,641
0.34%
82,641
0%
06/30/2018
SagePoint Financial, Inc. (Investment Management)
60,586
0.25%
32,026
0.01%
06/30/2018
SunTrust Banks, Inc. (Wealth Management)
43,668
0.18%
43,668
0%
06/30/2018
Bridgeway Capital Management, Inc.
40,000
0.17%
0
0%
06/30/2018
| Address |
8229 Boone Boulevard
Vienna Virginia 22182
United States
|
|
Employees
|
- |
| Website |
http://www.cel-sci.com |
| Updated |
07/08/2019 |
| CEL-SCI Corp. is a biotechnology company, which is involved in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers, and anal warts or cervical dysplasia in human immunodeficiency virus or human papillomavirus co-infected patients. |
